SEC INSIDER TRANSACTIONS

Medtronic plc (MDT) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

MDT · Medtronic plc

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-10-27 · 29 filings · fetched 2026-10-27T16:20:59Z

Recent reported activity

0purchase rows on this page

3sale rows on this page

59matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-10-15Filed 2026-10-16	Martha GeoffreyDirector · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 16, 2026. References:	S Sale (market/private)Ordinary Shares · Non-derivative	50,000D	95	Direct	Form 4 ↗0001560409-26-000011
2026-10-15Filed 2026-10-16	Marinaro MichaelOfficer · EVP, Pres MedSurg and Americas Filing context Reported filing row; may be amended. Do not sum filings blindly. This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 17, 2026. References:	S Sale (market/private)Ordinary Shares · Non-derivative	10,420D	96	Direct	Form 4 ↗0001984186-26-000010
2026-10-15Filed 2026-10-21	Lofton Kevin EDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 On October 15, 2026, 182 Medtronic plc ("Medtronic") ordinary shares beneficially owned by the Reporting Person were accepted for exchange in Medtronic's exchange offer for shares of common stock of MiniMed Group, Inc. ("MiniMed"). Pursuant to the exchange offer, the Reporting Person received 836 shares of MiniMed common stock based on the final exchange ratio of 4.5939 shares of MiniMed common stock for each Medtronic ordinary share accepted. F2 Includes 19 shares acquired through dividend reinvestment since the last report filed by the reporting person. References: F1, F2	J Other reported codeOrdinary Shares · Non-derivative	182D	—	Direct	Form 4 ↗0001468818-26-000008
2026-09-16Filed 2026-09-17	KIIL HARRY SKIPOfficer · EVP & President Cardiovascular Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	S Sale (market/private)Ordinary Shares · Non-derivative	1,483D	93.65	Direct	Form 4 ↗0001708062-26-000012
2026-09-15Filed 2026-09-16	Blomquist Denise L.Officer · Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	G GiftOrdinary Shares · Non-derivative	600D	0	Direct	Form 4 ↗0002061393-26-000014
2026-08-20Filed 2026-08-24	Marinaro MichaelOfficer · EVP, Pres MedSurg and Americas Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. References: F1	F WithholdingOrdinary Shares · Non-derivative	1,084D	92.3	Direct	Form 4 ↗0001984186-26-000008
2026-08-03Filed 2026-08-04	Thompson KweliOfficer · EVP & President, Neuroscience Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 188 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,306 shares will be issued. If maximum performance metrics are achieved, 41,534 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F7	A Award / grantStock Option (Right to Buy) · Derivative	49,167A	0	Direct	Form 4 ↗0002137804-26-000004
2026-08-03Filed 2026-08-04	Thompson KweliOfficer · EVP & President, Neuroscience Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 188 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,306 shares will be issued. If maximum performance metrics are achieved, 41,534 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F4, F5, F6	A Award / grantPerformance Share Units · Derivative	17,306A	0	Direct	Form 4 ↗0002137804-26-000004
2026-08-03Filed 2026-08-04	Thompson KweliOfficer · EVP & President, Neuroscience Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 188 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,306 shares will be issued. If maximum performance metrics are achieved, 41,534 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F3	A Award / grantOrdinary Shares · Non-derivative	6,923A	0	Direct	Form 4 ↗0002137804-26-000004
2026-08-03Filed 2026-08-04	Blomquist Denise L.Officer · Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 136 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 2,337 shares will be issued. If maximum performance metrics are achieved, 5,609 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F7	A Award / grantStock Option (Right to Buy) · Derivative	1,366A	0	Direct	Form 4 ↗0002061393-26-000012
2026-08-03Filed 2026-08-04	Blomquist Denise L.Officer · Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 136 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 2,337 shares will be issued. If maximum performance metrics are achieved, 5,609 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F4, F5, F6	A Award / grantPerformance Share Units · Derivative	2,337A	0	Direct	Form 4 ↗0002061393-26-000012
2026-08-03Filed 2026-08-04	Blomquist Denise L.Officer · Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 136 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 2,337 shares will be issued. If maximum performance metrics are achieved, 5,609 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F3	A Award / grantOrdinary Shares · Non-derivative	2,337A	0	Direct	Form 4 ↗0002061393-26-000012
2026-08-03Filed 2026-08-04	Pieton ThierryOfficer · EVP & Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F2 Includes 534 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F5 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 28,842 shares will be issued. If maximum performance metrics are achieved, 69,221 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F6	A Award / grantStock Option (Right to Buy) · Derivative	81,945A	0	Direct	Form 4 ↗0002056622-26-000003
2026-08-03Filed 2026-08-04	Pieton ThierryOfficer · EVP & Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F2 Includes 534 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F5 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 28,842 shares will be issued. If maximum performance metrics are achieved, 69,221 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F3, F4, F5	A Award / grantPerformance Share Units · Derivative	28,842A	0	Direct	Form 4 ↗0002056622-26-000003
2026-08-03Filed 2026-08-04	Pieton ThierryOfficer · EVP & Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F2 Includes 534 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F5 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 28,842 shares will be issued. If maximum performance metrics are achieved, 69,221 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F1, F2	A Award / grantOrdinary Shares · Non-derivative	11,537A	0	Direct	Form 4 ↗0002056622-26-000003
2026-08-03Filed 2026-08-04	Walter Matthew R.Officer · SVP, Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 140 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 14,421 shares will be issued. If maximum performance metrics are achieved, 34,610 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F7	A Award / grantStock Option (Right to Buy) · Derivative	40,973A	0	Direct	Form 4 ↗0002028475-26-000010
2026-08-03Filed 2026-08-04	Walter Matthew R.Officer · SVP, Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 140 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 14,421 shares will be issued. If maximum performance metrics are achieved, 34,610 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F4, F5, F6	A Award / grantPerformance Share Units · Derivative	14,421A	0	Direct	Form 4 ↗0002028475-26-000010
2026-08-03Filed 2026-08-04	Walter Matthew R.Officer · SVP, Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 140 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 14,421 shares will be issued. If maximum performance metrics are achieved, 34,610 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F3	A Award / grantOrdinary Shares · Non-derivative	5,769A	0	Direct	Form 4 ↗0002028475-26-000010
2026-08-03Filed 2026-08-04	Marinaro MichaelOfficer · EVP, Pres MedSurg and Americas Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 547 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Represents restricted stock units that vest in four annual installments beginning one year from the date of grant. F5 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F7 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 27,400 shares will be issued. If maximum performance metrics are achieved, 65,760 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F8 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F8	A Award / grantStock Option (Right to Buy) · Derivative	77,848A	0	Direct	Form 4 ↗0001984186-26-000006
2026-08-03Filed 2026-08-04	Marinaro MichaelOfficer · EVP, Pres MedSurg and Americas Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 547 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Represents restricted stock units that vest in four annual installments beginning one year from the date of grant. F5 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F7 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 27,400 shares will be issued. If maximum performance metrics are achieved, 65,760 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F8 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F5, F6, F7	A Award / grantPerformance Share Units · Derivative	27,400A	0	Direct	Form 4 ↗0001984186-26-000006
2026-08-03Filed 2026-08-04	Marinaro MichaelOfficer · EVP, Pres MedSurg and Americas Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 547 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Represents restricted stock units that vest in four annual installments beginning one year from the date of grant. F5 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F7 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 27,400 shares will be issued. If maximum performance metrics are achieved, 65,760 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F8 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F4	A Award / grantOrdinary Shares · Non-derivative	46,147A	0	Direct	Form 4 ↗0001984186-26-000006
2026-08-03Filed 2026-08-04	Marinaro MichaelOfficer · EVP, Pres MedSurg and Americas Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 547 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Represents restricted stock units that vest in four annual installments beginning one year from the date of grant. F5 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F7 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 27,400 shares will be issued. If maximum performance metrics are achieved, 65,760 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F8 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F3	A Award / grantOrdinary Shares · Non-derivative	10,960A	0	Direct	Form 4 ↗0001984186-26-000006
2026-08-03Filed 2026-08-04	Quinn MichelleOfficer · EVP, GC and Secretary Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F2 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F4 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 15,863 shares will be issued. If maximum performance metrics are achieved, 38,071 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F5 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F5	A Award / grantStock Option (Right to Buy) · Derivative	45,070A	0	Direct	Form 4 ↗0001964281-26-000004
2026-08-03Filed 2026-08-04	Quinn MichelleOfficer · EVP, GC and Secretary Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F2 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F4 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 15,863 shares will be issued. If maximum performance metrics are achieved, 38,071 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F5 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F2, F3, F4	A Award / grantPerformance Share Units · Derivative	15,863A	0	Direct	Form 4 ↗0001964281-26-000004
2026-08-03Filed 2026-08-04	Quinn MichelleOfficer · EVP, GC and Secretary Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F2 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F4 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 15,863 shares will be issued. If maximum performance metrics are achieved, 38,071 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F5 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F1	A Award / grantOrdinary Shares · Non-derivative	6,346A	0	Direct	Form 4 ↗0001964281-26-000004

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.